Dimethyloxaloylglycine
CAS No. 89464-63-1
Dimethyloxaloylglycine ( DMOG )
产品货号. M16443 CAS No. 89464-63-1
DMOG 是 α-酮戊二酸辅因子的拮抗剂和 HIF 脯氨酰羟化酶的抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
25MG | ¥381 | 有现货 |
|
50MG | ¥470 | 有现货 |
|
100MG | ¥729 | 有现货 |
|
200MG | ¥1312 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Dimethyloxaloylglycine
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述DMOG 是 α-酮戊二酸辅因子的拮抗剂和 HIF 脯氨酰羟化酶的抑制剂。
-
产品描述DMOG is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolyl hydroxylase.(In Vitro):DMOG efficiently suppresses hydroxyproline synthesis in intact cells, but shows only weakly active in the microsomal system.?DMOG reduces FGF-2-induced proliferation and cyclin A expression by inhibiting prolyl hydroxylase activity in HPASMC.(In Vivo):DMOG inhibits endogenous HIF inactivation, and induces angiogenesis in ischaemic skeletal muscles of mice. Up-regulation of hypoxia-inducible factor-1α by DMOG enhances the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats.
-
体外实验DMOG efficiently suppresses hydroxyproline synthesis in intact cells, but shows only weakly active in the microsomal system.?DMOG reduces FGF-2-induced proliferation and cyclin A expression by inhibiting prolyl hydroxylase activity in HPASMC.
-
体内实验DMOG inhibits endogenous HIF inactivation, and induces angiogenesis in ischaemic skeletal muscles of mice. Up-regulation of hypoxia-inducible factor-1α by DMOG enhances the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats.
-
同义词DMOG
-
通路Angiogenesis
-
靶点HIF/HIF Prolyl-hydroxylase
-
受体HIF-PH
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number89464-63-1
-
分子量175.14
-
分子式C6H9NO5
-
纯度>98% (HPLC)
-
溶解度Soluble in DMSO
-
SMILESO=C(OC)CNC(C(OC)=O)=O
-
化学全称N-(methoxyoxoacetyl)-glycine, methyl ester
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Baader E, et al. Biochem J. 1994, 300 ( Pt 2), 525-530.
产品手册
关联产品
-
Vadadustat
Vadadustat (PG-1016548, AKB-6548) 是一种新型、有效、口服活性的 HIF-PH 抑制剂,正在开发中,用于治疗非透析依赖性 (NDD) 和透析依赖性 CKD 患者的贫血。
-
Roxadustat
Roxadustat (FG4592, FG-4592) 是一种有效的口服 HIF 脯氨酰羟化酶 (HIF-PHD),IC50 为 591.4 nM。
-
KC7F2
一种小分子 HIF-1α 翻译抑制剂,IC50 为 20 uM。